Secondary amyloidosis is a severe complication of refractory rheumatoid arthritis for which no effective treatment exists. Although the benefits of tumor necrosis factor alpha inhibitors in rheumatoid arthritis treatment are well known, their role in renal amyloidosis secondary to rheumatoid arthritis is unclear and their safety in patients with chronic kidney disease is not well reported. We present an unusual case of a 65-year-old female with moderate renal failure and severe proteinuria, who was diagnosed with secondary amyloidosis associated with refractory rheumatoid arthritis subsequent to treatment with corticosteroids, methotrexate, hydroxychlorquine, and leflunomide. She was treated with etanercept 25 mg, administered as a subcutaneous injection twice weekly for 8 months. The patient had no complications following the treatment. Treatment with etanercept led to a decrease in proteinuria and stabilization of renal function over time.
Introduction
It has been reported that some patients with poorly controlled rheumatoid arthritis (RA) have complicated to secondary amyloidosis (1) . Successful treatment with multiple disease-modifying antirheumatic drugs (DMARDs) can lead to stabilization of organ function or improvement in function of the involved organ and partial resolution of amyloid deposits (2) . Unless the activity of the underlying disease can be effectively controlled, the development of secondary amyloidosis is associated with poor prognosis and reduces the survival rate of these patients (1) . In addition, there are considerable difficulties in the treatment of RA patients, who already have impaired renal function because several DMARDs such as methotrexate, cyclosporine, non-steroidal anti-inflammatory drugs (NSAIDs) may contribute to additional nephrotoxicity in these patients.
Due to the possibility of controlling the inflammatory activity, it has been suggested that anti-tumor necrosis factor-alpha (TNF-α) agents could be the best treatment option for secondary amyloidosis (3). Anti-TNF-α agents also have emerged as an effective treatment for refractory RA patients (4).
However, experience with anti-TNF-α agents in patients with secondary amyloidosis and renal insufficiency is scarce in Korea.
Herein, we describe the case of a patient with secondary amyloidosis and renal failure associated with refractory RA, who was successfully treated with etanercept.
Case Report
A 65 year old female with rheumatoid factor positive RA for the past 6 years presented with aggressive disease: rheumatoid factor 310 IU/mL, anti-cyclic citrullinated peptide antibody ＞100 U/mL, erythrocyte sediment rate (ESR) 120 mm/hr, and C-reactive protein (CRP) 11.06 mg/dL at the time of her first visit to the department. Despite treatment with corticosteroids, methotrexate, hydroxychlorquine, and leflunomide, she had experienced persistent joint pain and swelling involving hands, feet and ankles. 
Summary
Our report suggests that etanercept therapy may be useful in RA patients with renal failure induced by secondary amyloidosis. This treatment can significantly reduce proteinuria and also can stabilize renal function in refractory RA patients with renal failure and secondary amyloidosis.
